Marjon H Cnossen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7926623/publications.pdf

Version: 2024-02-01

127	2,713	185998	233125
papers	citations	28 h-index	45 g-index

131	131	131	2626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Healthâ€related quality of life in infants, toddlers and young children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29358.	0.8	6
2	In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients. European Journal of Clinical Pharmacology, 2022, 78, 237-249.	0.8	2
3	Treatment of patients with rare bleeding disorders in the Netherlands: Realâ€life data from the RBiN study. Journal of Thrombosis and Haemostasis, 2022, 20, 833-844.	1.9	9
4	Patientâ€reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	1.0	7
5	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokineticâ€pharmacodynamic model for patients with haemophilia A. British Journal of Clinical Pharmacology, 2022, 88, 2757-2768.	1.1	6
6	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	0.7	1
7	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study. BMJ Open, 2022, 12, e049493.	0.8	2
8	Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137.	1.9	17
9	Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, openâ€label study. American Journal of Hematology, 2022, 97, .	2.0	21
10	Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia, 2022, 28, 278-285.	1.0	1
11	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Advances, 2022, 6, 5317-5326.	2.5	2
12	Does difference between label and actual potency of factor VIII concentrate affect pharmacokineticâ€guided dosing of replacement therapy in haemophilia A?. Haemophilia, 2022, , .	1.0	2
13	Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. Haemophilia, 2022, 28, 814-821.	1.0	1
14	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	2.5	10
15	Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype. HemaSphere, 2022, 6, e718.	1.2	2
16	Deep compartment models: A deep learning approach for the reliable prediction of timeâ€series data in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 934-945.	1.3	8
17	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	1.9	6
18	The association between desmopressin exposure, FVIII response and side effects. Haemophilia, 2021, 27, e506-e509.	1.0	0

#	Article	IF	Citations
19	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	1.1	6
20	Oxygen gradient ektacytometryâ€derived biomarkers are associated with vasoâ€occlusive crises and correlate with treatment response in sickle cell disease. American Journal of Hematology, 2021, 96, E29-E32.	2.0	21
21	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. Clinical Pharmacokinetics, 2021, 60, 1-16.	1.6	3
22	Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding. Journal of Thrombosis and Haemostasis, 2021, 19, 719-731.	1.9	5
23	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. HemaSphere, 2021, 5, e542.	1.2	5
24	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine, 2021, 32, 100726.	3.2	30
25	Population pharmacokinetics of the von Willebrand factorâ€“factor VIII interaction in patients with von Willebrand disease. Blood Advances, 2021, 5, 1513-1522.	2.5	5
26	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	1.0	20
27	Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia. BMJ Case Reports, 2021, 14, e238036.	0.2	0
28	Outcome of Surgical Interventions and Deliveries in Patients with Bleeding of Unknown Cause: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1409-1416.	1.8	7
29	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. British Journal of Clinical Pharmacology, 2021, 87, 4408-4420.	1.1	4
30	Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency. Blood Advances, 2021, 5, 2339-2349.	2.5	7
31	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	2.2	9
32	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. Haemophilia, 2021, 27, 974-983.	1.0	3
33	Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. Blood Advances, 2021, 5, 4314-4325.	2.5	3
34	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. Thrombosis and Haemostasis, 2021, 121, 731-740.	1.8	5
35	Generic PROMIS item banks in adults with hemophilia for patientâ€reported outcome assessment: Feasibility, measurement properties, and relevance. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12621.	1.0	8
36	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PÂ®/Humate PÂ® treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	1.9	6

#	Article	IF	Citations
37	Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood Advances, 2020, 4, 5025-5034.	2.5	19
38	Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. Pediatric Blood and Cancer, 2020, 67, e28588.	0.8	5
39	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. Thrombosis and Haemostasis, 2020, 120, 1407-1416.	1.8	3
40	The oneâ€stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in nonâ€severe haemophilia A: Superiority or nonâ€inferiority?. Haemophilia, 2020, 26, 916-922.	1.0	3
41	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	1.8	8
42	Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis. BMC Medicine, 2020, 18, 393.	2.3	30
43	ADAMTSâ€13 and bleeding phenotype in von Willebrand disease. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1331-1339.	1.0	3
44	Performance of factor IX extended halfâ€life product measurements in external quality control assessment programs. Journal of Thrombosis and Haemostasis, 2020, 18, 1874-1883.	1.9	8
45	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	1.8	5
46	Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study. Haemophilia, 2020, 26, e106-e115.	1.0	15
47	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatographyâ€“Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2020, 42, 880-885.	1.0	1
48	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. Haemophilia, 2019, 25, 960-968.	1.0	4
49	Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Reviews, 2019, 37, 100580.	2.8	42
50	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. BMJ Open, 2019, 9, e022719.	0.8	7
51	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 2019, 94, E201-E205.	2.0	15
52	Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery. BMJ Case Reports, 2019, 12, bcr-2018-226812.	0.2	2
53	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. American Journal of Hematology, 2019, 94, 575-584.	2.0	47
54	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Advances, 2019, 3, 4147-4154.	2.5	12

#	Article	IF	Citations
55	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Therapeutic Drug Monitoring, 2019, 41, 192-212.	1.0	10
56	Sports participation and physical activity in patients with von Willebrand disease. Haemophilia, 2019, 25, 101-108.	1.0	14
57	Analytical variation in factor VIII oneâ€stage and chromogenic assays: Experiences from the ECAT external quality assessment programme. Haemophilia, 2019, 25, 162-169.	1.0	20
58	Analysis of current perioperative management with Haemate^{Â®} P/Humate P^{Â®} in von Willebrand disease: Identifying the need for personalized treatment. Haemophilia, 2018, 24, 460-470.	1.0	28
59	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. Blood Reviews, 2018, 32, 265-271.	2.8	41
60	Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease. British Journal of Haematology, 2018, 180, 432-442.	1.2	14
61	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. Thrombosis and Haemostasis, 2018, 118, 152-160.	1.8	15
62	Perioperative replacement therapy in haemophilia B: An appeal to â€œBâ€•more precise. Haemophilia, 2018, 24, 611-618.	1.0	7
63	Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. Thrombosis and Haemostasis, 2018, 118, 514-525.	1.8	19
64	Clinically relevant differences between assays for von Willebrand factor activity. Journal of Thrombosis and Haemostasis, 2018, 16, 2413-2424.	1.9	26
65	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostasis, 2018, 16, 2196-2207.	1.9	9
66	Defining patient value in haemophilia care. Haemophilia, 2018, 24, 516-518.	1.0	1
67	Positioning extended halfâ€life concentrates for future use: a practical proposal. Haemophilia, 2018, 24, e369-e372.	1.0	4
68	Pharmacokinetics and the transition to extended halfâ€life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1437-1441.	1.9	43
69	Comorbidities associated with higher von Willebrand factor (<scp>VWF</scp>) levels may explain the ageâ€related increase of <scp>VWF</scp> in von Willebrand disease. British Journal of Haematology, 2018, 182, 93-105.	1.2	39
70	Identifying Children with HEreditary Coagulation disorders (iCHEC): a protocol for a prospective cohort study. BMJ Open, 2018, 8, e020686.	0.8	3
71	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and Haemostasis, 2018, 47, 621-629.	1.8	8
72	The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia. Blood, 2018, 132, 2360-2360.	0.6	1

#	Article	IF	Citations
73	Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen. Haemophilia, 2017, 23, 861-867.	1.0	5
74	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	1.7	24
75	Gene Variations in the Protein C and Fibrinolytic Pathway: Relevance for Severity and Outcome in Pediatric Sepsis. Seminars in Thrombosis and Hemostasis, 2017, 43, 036-047.	1.5	2
76	In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. Journal of Thrombosis and Haemostasis, 2017, 15, 1737-1746.	1.9	12
77	Current and Emerging Options for the Management of Inherited von Willebrand Disease. Drugs, 2017, 77, 1531-1547.	4.9	28
78	Sensorâ€based gait analysis as a simple tool to measure gait in haemophilia patients. Haemophilia, 2017, 23, e355-e358.	1.0	3
79	Pitfalls in the diagnosis of hemophilia severity: What to do?. Pediatric Blood and Cancer, 2017, 64, e26276.	0.8	2
80	Joint assessment in von Willebrand disease. Thrombosis and Haemostasis, 2017, 117, 1465-1470.	1.8	8
81	Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation. BMJ Case Reports, 2016, 2016, bcr2016217069.	0.2	8
82	Circadian Variation of Plasminogen-Activator-Inhibitor-1 Levels in Children with Meningococcal Sepsis. PLoS ONE, 2016, 11, e0167004.	1.1	5
83	Facilitating the implementation of pharmacokineticâ€guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia, 2016, 22, e1-e10.	1.0	26
84	Side effects of desmopressin in patients with bleeding disorders. Haemophilia, 2016, 22, 39-45.	1.0	46
85	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
86	Defining adherence to prophylaxis in haemophilia. Haemophilia, 2016, 22, e311-4.	1.0	13
87	Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. British Journal of Haematology, 2016, 172, 274-284.	1.2	25
88	Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. Journal of Thrombosis and Haemostasis, 2016, 14, 468-478.	1.9	39
89	Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. Patient Education and Counseling, 2016, 99, 1179-1183.	1.0	14
90	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 2016, 101, 1159-1169.	1.7	39

#	Article	IF	Citations
91	Optimization of home treatment in haemophilia: effects of transmural support by a haemophilia nurse on adherence and quality of life. Haemophilia, 2016, 22, 841-851.	1.0	8
92	A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol. BMC Hematology, 2016, 16, 21.	2.6	4
93	Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. American Journal of Hematology, 2016, 91, 763-769.	2.0	48
94	Joint surgery in von Willebrand disease: a multicentre crossâ€sectional study. Haemophilia, 2016, 22, 256-262.	1.0	6
95	In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI. American Journal of Neuroradiology, 2016, 37, 1727-1732.	1.2	37
96	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. British Journal of Haematology, 2016, 174, 454-460.	1.2	46
97	Selfâ€infusion of prophylaxis: evaluating the quality of its performance and time needed. Haemophilia, 2016, 22, e214-7.	1.0	2
98	CLEC4M and STXBP5 gene variations contribute to vonÂWillebrand factor level variation in von Willebrand disease. Journal of Thrombosis and Haemostasis, 2015, 13, 956-966.	1.9	45
99	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 2015, 125, 3006-3013.	0.6	62
100	Bleeding spectrum in children with moderate or severe von <scp>W</scp>illebrand disease: <scp>R</scp>elevance of pediatricâ€specific bleeding. American Journal of Hematology, 2015, 90, 1142-1148.	2.0	46
101	Inhibitor development and mortality in nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2015, 13, 1217-1225.	1.9	65
102	The â€œOPTI-CLOTâ€•trial. Thrombosis and Haemostasis, 2015, 114, 639-644.	1.8	22
103	Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease. British Journal of Haematology, 2015, 168, 553-556.	1.2	55
104	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a crossâ€sectional study. Haemophilia, 2015, 21, e185-92.	1.0	43
105	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. Blood, 2015, 126, 3510-3510.	0.6	2
106	Reliability and validity of a novel Haemophiliaâ€specific Selfâ€Efficacy Scale. Haemophilia, 2014, 20, e267-74.	1.0	5
107	Desmopressin response in hemophilia A patients with FVIII:CÂ<Â0.10 IUÂmLâ^'1. Journal of Thrombosis and Haemostasis, 2014, 12, 110-112.	1.9	5
108	von Willebrand disease and aging: an evolving phenotype. Journal of Thrombosis and Haemostasis, 2014, 12, 1066-1075.	1.9	87

#	Article	IF	Citations
109	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the <scp>VERITAS</scp>â€Pro scale. Haemophilia, 2014, 20, 616-623.	1.0	32
110	Quality of life and behavioral functioning in Dutch pediatric patients with hereditary spherocytosis. European Journal of Pediatrics, 2014, 173, 1217-1223.	1.3	2
111	Reduced prevalence of arterial thrombosis in von Willebrand disease. Journal of Thrombosis and Haemostasis, 2013, 11, 845-854.	1.9	79
112	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	0.6	188
113	Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thrombosis and Haemostasis, 2013, 109, 440-449.	1.8	25
114	Diagnosis and management of haemophilia. BMJ, The, 2012, 344, e2707-e2707.	3.0	82
115	The group medical appointment (GMA) in haemophilia and von Willebrandâ€™s disease: a new development in outpatient paediatric care. Haemophilia, 2012, 18, 766-772.	1.0	4
116	Age dependency of coagulation parameters during childhood and puberty. Journal of Thrombosis and Haemostasis, 2012, 10, 2254-2263.	1.9	96
117	Relationship between neonatal screening results by HPLC and the number of Î±-thalassaemia gene mutations; consequences for the cut-off value. Journal of Medical Screening, 2011, 18, 182-186.	1.1	14
118	Paediatric arterial ischaemic stroke: functional outcome and risk factors. Developmental Medicine and Child Neurology, 2010, 52, 394-399.	1.1	85
119	Codon 24 (TAT>TAG) and Codon 32 (ATG>AGG) (Hb Rotterdam): Two Novel Î±2 Gene Mutations Associated with Mild Î±-Thalassemia Found in the Same Family After Newborn Screening. Hemoglobin, 2010, 34, 354-365.	0.4	6
120	Etiology and treatment of perinatal stroke; a role for prothrombotic coagulation factors?. Seminars in Fetal and Neonatal Medicine, 2009, 14, 311-317.	1.1	32
121	Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children < or = 6 years and clinically suspected of having NF1. Neurofibromatosis team of Sophia Children's Hospital.. Journal of Medical Genetics, 1998, 35, 624-627.	1.5	37
122	Familial neurofibromatosis type 1 associated with an overgrowth syndrome resembling Weaver syndrome.. Journal of Medical Genetics, 1998, 35, 323-327.	1.5	24
123	A prospective 10Âyear follow up study of patients with neurofibromatosis type 1. Archives of Disease in Childhood, 1998, 78, 408-412.	1.0	100
124	Endocrinologic Disorders and Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. Pediatrics, 1997, 100, 667-670.	1.0	86
125	Diagnostic delay in neurofibromatosis type 1. European Journal of Pediatrics, 1997, 156, 482-487.	1.3	22
126	Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1?. , 1997, 9, 458-464.		109

#	Article	IF	Citations
127	Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes. Journal of Clinical Immunology, 0, , .	2.0	1